HPV vaccination programmes have substantial impact in reducing HPV infections and precancerous cervical lesions

  • Drolet M & al.
  • Lancet
  • 26 Jun 2019

  • curated by Priscilla Lynch
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A meta-analysis of 60 million individuals in high-income countries has identified significant decreases in HPV infections, anogenital wart diagnoses and precancerous cervical lesions (CIN2+) over eight-to-nine years after HPV vaccination.

The new study, published in The Lancet, is the first to show pooled estimates of the population-level impact of HPV vaccination on CIN2+ from several countries, the benefit of vaccinating more than one age group, and substantial herd effects in countries achieving high vaccination coverage.

The systemic review and meta-analysis included 65 articles in 14 high-income countries – 23 for HPV infection, 29 for anogenital warts and 13 for CIN2+ lesions.

A decrease of 83 per cent of HPV 16 and 18 in girls aged 13-19 years and, 66 per cent in women aged 20-24 years, five to eight years after vaccination, was noted. An overall 54 per cent reduction was also seen in HPV 31, 33 and 45 in girls aged 13-19 years.

Five to nine years after vaccination CIN2+ decreased significantly: 51 per cent reduction in screened girls aged 15-19 years and a 31 per cent reduction in screened women aged 20-24 years.

There were also significant reductions (up to 88%) in anogenital wart diagnoses in both males and females.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit